Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
Checked against the public recordLast updated Dec 17, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Biological: BMS-986315; Biological: nivolumab; Biological: cetuximab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1 * Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor * Eastern cooperative oncology group performance status of 0 or 1 * Women of childbearing potential must agree to follow methods of contraception Exclusion Criteria: * Participants with active, known or suspected autoimmune disease * Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications * Uncontrolled or significant cardiovascular disease * History of or with active interstitial lung disease or pulmonary fibrosis * Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study * History of allergy or hypersensitivity to study drug components Other protocol-defined inclusion/exclusion criteria apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Local Institution - 0028Sioux Falls, South Dakota
- Local Institution - 0001Germantown, Tennessee
- Local Institution - 0014Edmonton, Alberta
- Local Institution - 0011Vancouver, British Columbia
- Local Institution - 0004Toronto, Ontario
- Local Institution - 0005Montreal, Quebec
- Local Institution - 0013Ottawa
- Local InstitutionMexico City, Mexico City
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 17, 2025. Always confirm current availability with the study team.